Immune response drives outcomes in prostate cancer: implications for immunotherapy-Reference-Cited by-同舟云学术

Immune response drives outcomes in prostate cancer: implications for immunotherapy

Published:2020-12-29 Issue:5 Volume:15 Page:1358-1375
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Mol Oncol

Author:

Meng Jialin¹²^ORCID,Zhou Yujie³,Lu Xiaofan⁴,Bian Zichen¹²,Chen Yiding¹²,Zhou Jun¹²,Zhang Li¹²,Hao Zongyao¹²,Zhang Meng¹²⁵,Liang Chaozhao¹²

Affiliation:

1. Department of Urology The First Affiliated Hospital of Anhui Medical University Hefei China

2. Institute of Urology & Anhui Province Key Laboratory of Genitourinary Diseases Anhui Medical University Hefei China

3. Division of Gastroenterology and Hepatology Key Laboratory of Gastroenterology and Hepatology Ministry of Health, Renji Hospital School of Medicine Shanghai Jiao Tong UniversityShanghai Institute of Digestive Disease China

4. State Key Laboratory of Natural Medicines Research Center of Biostatistics and Computational Pharmacy China Pharmaceutical University Nanjing China

5. Urology Institute of Shenzhen University The Third Affiliated Hospital of Shenzhen University Shenzhen University China

Funder

National Natural Science Foundation of China

Natural Science Foundation of Guangdong Province

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.12887

Reference61 articles.

1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods